D. Boral Capital Begins Coverage on Compass Therapeutics (NASDAQ:CMPX)

D. Boral Capital started coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a research note released on Monday morning, MarketBeat.com reports. The firm issued a buy rating and a $32.00 price objective on the stock.

Several other research analysts also recently weighed in on CMPX. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a report on Monday, September 16th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, November 11th. Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Compass Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $11.80.

Compass Therapeutics Stock Performance

Shares of NASDAQ:CMPX opened at $1.50 on Monday. Compass Therapeutics has a one year low of $0.77 and a one year high of $2.34. The stock has a market cap of $206.38 million, a PE ratio of -4.05 and a beta of 0.89. The business’s fifty day moving average price is $1.62 and its two-hundred day moving average price is $1.42.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. As a group, equities research analysts predict that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Rovin Capital UT ADV purchased a new position in Compass Therapeutics in the third quarter valued at approximately $25,000. Intech Investment Management LLC purchased a new position in shares of Compass Therapeutics in the 3rd quarter valued at $30,000. XTX Topco Ltd acquired a new position in shares of Compass Therapeutics during the 3rd quarter valued at $37,000. SG Americas Securities LLC boosted its position in Compass Therapeutics by 16.6% during the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after purchasing an additional 5,515 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in Compass Therapeutics in the 2nd quarter valued at $41,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.